Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP10155967A	2021-01-15	Keilitz Haines & Partner Patentanwälte PartGmbB	Granted and Under Opposition
EP10155967A	2020-04-15	ALK-ABELLO A/S	Granted and Under Opposition
EP05783727A	2016-11-02	Merck Patent GmbH	Revoked
EP05783727A	2016-11-02	ALK-ABELLO A/S	Revoked
EP05783727A	2016-10-28	Meridian Medical Technologies, Inc.	Revoked
EP09173753A	2016-07-28	Merck Patent GmbH	Patent maintained as amended
EP10194414A	2015-02-19	Feldmeier, Jürgen	Revoked
EP10194414A	2014-11-07	ALK-ABELLO A/S	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7449012	MYLAN SPECIALITY LP	Automatic injector	Sep, 2025 (1 year, 11 months from now)
US9586010	MYLAN SPECIALITY LP	Automatic injector with needle cover	Sep, 2025 (1 year, 11 months from now)
US8870827	MYLAN SPECIALITY LP	Automatic injector	Sep, 2025 (1 year, 11 months from now)
US7794432	MYLAN SPECIALITY LP	Automatic injector with kickback attenuation	Sep, 2025 (1 year, 11 months from now)
US8048035	MYLAN SPECIALITY LP	Automatic injector with needle cover	Sep, 2025 (1 year, 11 months from now)

Epi E Z Pen Jr is owned by Mylan Speciality Lp.

Epi E Z Pen Jr contains Epinephrine.

Epi E Z Pen Jr has a total of 5 drug patents out of which 0 drug patents have expired.

Epi E Z Pen Jr was authorised for market use on 22 December, 1987.

Epi E Z Pen Jr is available in injectable;intramuscular, subcutaneous dosage forms.

The generics of Epi E Z Pen Jr are possible to be released after 11 September, 2025.

Market Authorisation Date: 22 December, 1987

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.15 mg/0.3 mL and 0.3 mg/0.3 mL	20 Jul, 2009	1	16 Aug, 2018	11 Sep, 2025	Deferred

Strength	Dosage	Availability
0.15MG/DELIVERY	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
0.3MG/DELIVERY	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

EPI E Z PEN JR family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic